An Exhaustive Monograph on Aldesleukin (Proleukin®): From Foundational Immunobiology to its Evolving Role in Oncology

Introduction

Aldesleukin, commercially known as Proleukin®, occupies a unique and paradoxical position in the history of oncology. As a recombinant, non-glycosylated form of the human cytokine interleukin-2 (IL-2), it was one of the first agents to unequivocally demonstrate that the human immune system could be pharmacologically stimulated to eradicate metastatic cancer. Its introduction in the early 1990s represented a paradigm shift, establishing the field of cancer immunotherapy and offering, for the first time, the possibility of durable, long-term complete remissions for patients with advanced metastatic melanoma and metastatic renal cell carcinoma (mRCC).[1] For a small but significant subset of patients, Aldesleukin provided not just a treatment, but a cure. This remarkable efficacy, however, came at a profound cost. The drug’s mechanism of action—a potent, pleiotropic, and non-specific activation of the immune system—is inextricably linked to a formidable and often life-threatening toxicity profile, most notably the development of Capillary Leak Syndrome (CLS).[4]

This report presents an exhaustive analysis of Aldesleukin, arguing that its legacy is twofold and defines its current, highly specialized role in medicine. First, it exists as a historically significant but now niche therapeutic agent. Its severe risk profile and the requirement for intensive, inpatient care have led to its displacement by a new generation of better-tolerated and more broadly effective immunotherapies, such as immune checkpoint inhibitors. Second, and perhaps more importantly, Aldesleukin serves as a crucial catalyst for modern innovation. It remains an indispensable component for the successful administration of cutting-edge adoptive cell therapies, and its biological and clinical shortcomings have provided the scientific benchmark and the clinical imperative for the development of a new wave of safer, more targeted IL-2 analogs. This monograph will navigate the full arc of Aldesleukin’s story, from its molecular identity and complex pharmacology, through its clinical applications and turbulent commercial history, to a comparative analysis against modern standards of care and a forward-looking examination of the next generation of therapies that seek to perfect the powerful potential of the IL-2 pathway.

Section 1: Molecular Profile and Pharmaceutical Characteristics

The identity of Aldesleukin is rooted in its nature as a first-generation biotechnology product, engineered to mimic a natural human protein but bearing specific modifications dictated by the constraints and opportunities of its manufacturing process. A precise understanding of its structure and formulation is fundamental to appreciating its clinical behavior.

Nomenclature and Identifiers

Aldesleukin is recognized by a variety of names and chemical identifiers across scientific and regulatory domains. A consistent nomenclature is critical for accurate communication and research.

• Generic Name: Aldesleukin [8]
• Brand Name: Proleukin® [8]
• Chemical Name: 125-L-Serine-2-133-Interleukin 2 (human reduced).[8] This name reflects the specific amino acid substitution that distinguishes it from the native protein.
• Synonyms: A range of synonyms are used in literature, including Recombinant human IL-2, r-serHuIL-2, IL-2, and T-cell growth factor.[4]
• Key Database and Chemical Identifiers:
• DrugBank ID: DB00041 [12]
• CAS Number: 110942-02-4 [4]
• Molecular Formula: C690​H1115​N177​O203​S6​ [8]
• Molecular Weight: Approximately 15,300 daltons [7], with a more precise calculated weight of 15314.8 Da.[15]

Recombinant Origin and Structural Modifications

Aldesleukin is a lymphokine produced via recombinant DNA technology. It is not harvested from human sources but is expressed in a genetically engineered strain of the bacterium Escherichia coli (E. coli) that contains a modified analog of the human IL-2 gene.[4] The choice of an

E. coli expression system, a common and efficient platform in early biotechnology, necessitated several key structural modifications that differentiate Aldesleukin from the endogenous, native human IL-2. These differences are not trivial and have implications for the drug's biological properties and stability.

There are three critical distinctions from native human IL-2 [12]:

1. Non-glycosylation: Native human IL-2 is a glycoprotein, meaning it has sugar chains (glycans) attached to its protein backbone through a process called glycosylation.[14] E. coli, as a prokaryotic organism, lacks the cellular machinery to perform this complex post-translational modification. Consequently, Aldesleukin is produced as a non-glycosylated protein.[12] This structural difference can affect the molecule's solubility, stability, and pharmacokinetic profile compared to its native counterpart.
2. N-terminal Alanine Deletion: During the genetic engineering process, the codon for the N-terminal alanine amino acid was deliberately deleted from the gene inserted into the E. coli. This results in a final protein that is missing the first amino acid of the native sequence. This modification is reflected in its chemical name, "des-alanyl-1...".[7]
3. Serine-for-Cysteine Substitution at Position 125: The native human IL-2 protein contains a cysteine residue at amino acid position 125. Cysteine residues contain sulfur atoms that can form disulfide bonds with other cysteines. While essential for proper protein folding, an unpaired cysteine can lead to incorrect disulfide bond formation, causing the protein to misfold, aggregate, or form inactive dimers. To enhance the stability and manufacturing consistency of the recombinant protein, the gene was modified via site-specific mutagenesis to substitute this cysteine with a serine residue.[12] Serine is structurally similar to cysteine but lacks the reactive sulfhydryl group, thus preventing aberrant bonding and improving the homogeneity of the final drug product.

These modifications represent a classic example of the engineering trade-offs inherent in early biopharmaceutical development. The use of a robust, high-yield E. coli system was prioritized for manufacturability, but this required sacrificing native-like structure (glycosylation) and introducing specific mutations to ensure the stability and activity of the final molecule.

Pharmaceutical Formulation and Administration

The physical form of Aldesleukin and the strict protocols for its preparation and administration are dictated by its potency and potential for severe toxicity.

• Formulation: Aldesleukin is supplied as a sterile, white to off-white, preservative-free lyophilized (freeze-dried) cake in single-use glass vials. Each vial contains 22 million International Units (IU) of the drug, which is equivalent to 1.3 mg of protein.[7] The manufacturing process utilizes tetracycline hydrochloride in the fermentation medium, but the antibiotic is not detectable in the final purified product.[7]
• Reconstitution and Dilution: The preparation for intravenous administration is a critical multi-step process that must be performed with care to avoid compromising the drug's integrity.

1. Reconstitution: The vial containing 22 million IU is reconstituted by adding 1.2 mL of Sterile Water for Injection. The sterile water should be directed toward the side of the vial, and the vial should be gently swirled, not shaken, to dissolve the cake. Shaking can cause excessive foaming and denaturation of the protein. This reconstituted solution has a final concentration of 18 million IU/mL (1.1 mg/mL).[8]
2. Dilution: The appropriate dose, calculated based on patient weight, is then withdrawn from the reconstituted vial and added to a 50 mL infusion bag of 5% Dextrose Injection (D5W). The manufacturer specifies that the final concentration of Aldesleukin in the infusion bag should be maintained within the range of 30 to 70 mcg/mL. Using concentrations outside this range can lead to increased variability in drug delivery and is not recommended for short-duration infusions.[8]

• Administration: Aldesleukin is administered as a short-duration (15-minute) intravenous infusion.[7] Due to the high risk of severe and life-threatening toxicities, administration must take place in a hospital setting under the supervision of a qualified physician experienced in the use of antineoplastic agents. Critically, an intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be immediately available to manage potential adverse events.[7]
• Potency Units: The potency of Aldesleukin is expressed in International Units (IU). It is important to note that other units, such as Cetus Units (CU) or Roche Units (RU), have been used in historical literature and are not equivalent (e.g., 1 CU = 6 IU). Care must be exercised when interpreting dosages from different sources to avoid medication errors.[8]

Section 2: Mechanism of Action and Pharmacokinetics

Aldesleukin exerts its therapeutic effects through a powerful and broad stimulation of the immune system, a process initiated by a specific molecular signaling cascade. Its pharmacokinetic profile, particularly its rapid clearance from the body, dictates its intensive and challenging clinical dosing schedule.

Pharmacodynamics: The IL-2 Signaling Cascade

Aldesleukin functions as a recombinant analog of endogenous IL-2, binding to and activating the IL-2 receptor (IL-2R) to trigger a cascade of intracellular events that ultimately drive immune cell proliferation and activation.[9]

• Receptor Binding and Activation: The IL-2 receptor exists in three forms with varying affinities for IL-2, determined by its subunit composition: the low-affinity IL-2Rα (also known as CD25), the intermediate-affinity dimer of IL-2Rβ (CD122) and the common gamma chain (IL-2Rγ or CD132), and the high-affinity trimeric complex of IL-2Rα, IL-2Rβ, and IL-2Rγ.[14] Aldesleukin binds to these receptors, initiating a conformational change that activates downstream signaling pathways.[12]
• Intracellular Signal Transduction: The binding of Aldesleukin to the IL-2R complex triggers a precise and well-defined signaling cascade [9]:

1. The binding event induces the heterodimerization of the cytoplasmic domains of the IL-2Rβ and IL-2Rγ subunits.
2. This dimerization brings the associated Janus kinase 3 (Jak3) into close proximity, leading to its activation.
3. Activated Jak3 then phosphorylates key tyrosine residues on the intracellular tail of the IL-2Rβ chain.
4. These phosphorylated tyrosine sites act as docking stations for various cytoplasmic signaling molecules, most notably Signal Transducer and Activator of Transcription (STAT) proteins, which are recruited to the activated receptor complex and subsequently phosphorylated.
5. Activated STAT proteins then translocate to the nucleus, where they act as transcription factors to regulate the expression of genes critical for immune cell function.

Immunomodulatory Effects

The molecular signaling initiated by Aldesleukin translates into a wide array of powerful, pleiotropic effects on the immune system, which collectively mediate its antitumor activity.[4]

• Lymphocyte Proliferation and Expansion: Aldesleukin is a potent mitogen for lymphocytes, stimulating their division and proliferation. It is particularly crucial for the long-term growth of IL-2-dependent T-cell lines and the expansion of naive T-cells into effector and memory populations.[9] This results in a profound lymphocytosis observed in treated patients.[5]
• Enhanced Cytotoxicity: The drug significantly enhances the tumor-killing capacity of multiple immune effector cells. It induces and stimulates the cytotoxic activity of Natural Killer (NK) cells, Lymphokine-Activated Killer (LAK) cells, and antigen-specific Cytotoxic T-Lymphocytes (CTLs).[9] These activated cells are better able to recognize and destroy tumor cells.
• Induction of Secondary Cytokines: Aldesleukin does not act in isolation. Its stimulation of immune cells leads to the production and release of other important pro-inflammatory cytokines, creating a broader immune cascade. These induced cytokines include Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-1 (IL-1).[4] IFN-γ, in particular, has its own direct and indirect antitumor effects.
• Other Hematologic Effects: In addition to lymphocytosis, treatment is characterized by eosinophilia and thrombocytopenia.[5]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The movement of Aldesleukin through the body is characterized by rapid distribution and very fast clearance, a profile that has profound clinical implications. The key pharmacokinetic parameters are consolidated in Table 1.

• Absorption: Aldesleukin is a protein and is not orally bioavailable; it would be digested in the gastrointestinal tract. Therefore, it requires parenteral administration.[5] The primary route is intravenous infusion, though subcutaneous and intralesional routes have also been utilized in clinical and investigational settings.[5]
• Distribution: Following IV infusion, the drug is rapidly distributed from the plasma compartment into various tissues and organs, with preferential uptake observed in the lungs, liver, kidney, and spleen.[5] Its volume of distribution is relatively small, estimated at 4-7 L.[5]
• Metabolism: The primary site of Aldesleukin metabolism and clearance is the kidney. It is not metabolized by the liver in the same way as small-molecule drugs. Instead, greater than 80% of the circulating drug is filtered by the glomeruli and taken up by the cells lining the proximal convoluted tubules. Inside these cells, the protein is catabolized and broken down into its constituent amino acids, which are then reabsorbed and returned to the body's metabolic pool.[4] This process results in no active metabolites; the drug is completely inactivated.[5]
• Elimination: Elimination of the intact drug from the body is minimal. Because it is almost entirely metabolized to amino acids in the kidneys, only trace amounts, if any, of active Aldesleukin are excreted in the urine.[5] The drug exhibits a two-compartmental disposition model.[21]
• Half-Life and Clearance: The most striking feature of Aldesleukin's pharmacokinetics is its extremely short biological half-life. Following intravenous administration, the terminal half-life is reported to be between 13 and 85 minutes [4], with some sources citing a range of 80-120 minutes.[5] This rapid clearance is driven by a high systemic clearance rate of approximately 268 mL/min.[5]

The very short half-life is a direct cause of the drug's demanding clinical administration schedule. To maintain therapeutically active concentrations of the drug in the body, it must be administered frequently, leading to the intensive regimen of an infusion every 8 hours.[7] This repeated, high-dose administration, required to overcome the rapid clearance, is the primary driver of the cumulative toxicity that characterizes Aldesleukin therapy, including the development of severe adverse events like Capillary Leak Syndrome. This pharmacokinetic profile created a clear and compelling rationale for subsequent research into next-generation IL-2 analogs, with a major engineering goal being the extension of the molecule's half-life to allow for less frequent, lower, and safer dosing.

Table 1: Pharmacokinetic Parameters of Aldesleukin

Parameter	Value / Description	Source(s)
Administration Routes	Intravenous (IV) infusion, Subcutaneous (SC), Intralesional	5
Oral Bioavailability	None	5
Distribution	Rapid; primarily to lungs, liver, kidney, spleen	5
Volume of Distribution (Vd​)	4-7 L	5
Metabolism Site	Primarily renal; catabolized in proximal convoluted tubules	4
Primary Metabolites	Inactive constituent amino acids	4
Elimination	Primarily via renal metabolism; minimal excretion of intact drug	5
Terminal Half-Life (IV)	13-85 minutes (or 80-120 minutes)	4
Clearance	~268 mL/min	5

Section 3: Clinical Efficacy and Therapeutic Applications

The clinical journey of Aldesleukin is one of groundbreaking success in narrow indications, followed by extensive but ultimately unsuccessful investigation in other diseases, and a modern-day resurgence as a critical component of complex, next-generation cancer therapies.

FDA-Approved Indications

Aldesleukin holds FDA approval for two specific types of metastatic cancer. Its approval in these settings was based not on high overall response rates, but on its unique ability to induce exceptionally durable, long-lasting complete remissions in a small subset of patients, effectively curing them of their advanced disease.[1]

• Metastatic Renal Cell Carcinoma (mRCC): Aldesleukin was first approved by the FDA in 1992 for the treatment of adults with mRCC.[1] The initial approval was based on data from seven Phase 2 trials involving 255 patients, which showed an overall objective response rate (ORR) of 14%.[1] While modest, the durability of these responses was unprecedented. A later prospective study, the Cytokine Working Group "Select" trial, demonstrated that with improved patient selection criteria, the ORR could be increased to 25% (30 out of 120 patients), with 11% of patients remaining progression-free at 3 years and a median overall survival of 42.8 months.[1]
• Metastatic Melanoma: Following its success in mRCC, Aldesleukin received FDA approval in 1998 for the treatment of adults with metastatic melanoma.[10] The efficacy profile is similar to that in mRCC, with an ORR of approximately 16%, including a 6% complete response (CR) rate.[3] As with kidney cancer, the hallmark of its efficacy in melanoma is the profound durability of the responses in the small number of patients who benefit.[3]

Historical and Investigational Uses

The initial success of Aldesleukin prompted widespread investigation into its potential use across a variety of other diseases, particularly those involving immune dysregulation. However, these efforts did not lead to further regulatory approvals.

• Human Immunodeficiency Virus (HIV) Infections: In the 1990s, before the advent of highly active antiretroviral therapy (HAART), there was significant interest in using Aldesleukin as an immune-boosting agent. The rationale was that it could stimulate T-cell proliferation and help restore immune function in immunocompromised patients. Multiple Phase 1 clinical trials were completed, often combining Aldesleukin with early antiretroviral drugs like Zidovudine (AZT), to assess its safety and effectiveness in both HIV-infected adults and children.[25] Despite these early-phase studies, this line of investigation was ultimately discontinued, likely due to a combination of toxicity concerns and the subsequent success of combination antiretroviral therapies that effectively control the virus.[26]
• Lymphoma: Aldesleukin was evaluated in completed Phase 2 and Phase 3 trials for the treatment of various lymphomas.[27] It was often studied in aggressive settings, such as for refractory or relapsed Hodgkin's lymphoma, typically as part of an intensive regimen following high-dose myeloablative chemotherapy and autologous stem cell transplantation.[27] This indication was also discontinued and did not achieve regulatory approval.[26]
• Brain and Central Nervous System Tumors: Completed Phase 2 trials explored the use of Aldesleukin for aggressive brain tumors, including glioblastoma multiforme, astrocytoma, and oligodendroglioma.[28] It was almost always used as part of a multi-modal approach, in combination with surgery, radiation, chemotherapy (e.g., carmustine, cisplatin), and other biological therapies like vaccine therapy or cellular adoptive immunotherapy.[28]

The Current Clinical Trial Landscape: A New Role

While Aldesleukin is no longer a frontline monotherapy for its approved indications, it has found a new and vital role in modern oncology, as demonstrated by the landscape of ongoing clinical trials. Its contemporary use falls into two main categories: as a synergistic partner for newer immunotherapies and as an essential support agent for adoptive cell therapies.

• Combination with Immune Checkpoint Inhibitors (CPIs): A major focus of current research is to determine if Aldesleukin can provide additional benefit when combined with PD-1/PD-L1 checkpoint inhibitors, particularly for patients whose cancers have become refractory to CPIs alone.
• The Phase 2 trial NCT05155033 is actively recruiting patients with metastatic melanoma and mRCC to evaluate the combination of Aldesleukin and the anti-PD-1 antibody pembrolizumab.[29] This study specifically targets patients with melanoma refractory to anti-PD-1 therapy and patients with mRCC refractory to at least one line of PD-1/PD-L1 based therapy, addressing a critical unmet need.
• Other trials are exploring similar combinations, such as high-dose Aldesleukin with the ipilimumab/nivolumab combination for Stage III-IV melanoma.[31]
• Essential Component of Adoptive Cell Therapy (ACT): Perhaps the most critical modern role for Aldesleukin is as a mandatory component of Tumor-Infiltrating Lymphocyte (TIL) therapy. In this approach, a patient's own tumor-killing T-cells are harvested from their tumor, expanded to massive numbers in the lab, and then re-infused. After infusion, these TILs require a powerful growth signal to proliferate and survive in vivo to attack the cancer. Aldesleukin provides this essential signal.
• Numerous active clinical trials for a wide range of solid cancers—including metastatic melanoma, uveal melanoma, biliary tract cancers, non-small cell lung cancer (NSCLC), and other solid tumors—use Aldesleukin as a required post-infusion support agent.[31] Trials like NCT05296564, which investigates TCR-gene engineered lymphocytes, explicitly list Aldesleukin as part of the treatment protocol.[32] This essential role in ACT is a primary driver of Aldesleukin's continued clinical relevance.
• Novel Combinations: Research continues to explore Aldesleukin in other novel contexts. For example, trial NCT05802056 is investigating its use in combination with nivolumab and standard chemotherapy (FOLFOX) for gastric cancer with peritoneal metastasis, a very difficult-to-treat condition.[34] Other studies are pairing it with emerging technologies like cytokine-induced memory-like NK cells.[31]

The current research landscape clearly illustrates a strategic pivot. Aldesleukin is no longer viewed as a standalone solution but as a powerful tool to be used selectively and strategically. Its future is not as a monotherapy but as a critical enabling component of more complex and targeted therapeutic regimens, a fact underscored by the ongoing trials listed in Table 2.

Table 2: Selected Ongoing Clinical Trials Involving Aldesleukin

NCT Identifier	Indication(s)	Phase	Intervention(s)	Status	Source(s)
NCT05155033	Metastatic Melanoma (refractory to anti-PD-1), Metastatic Renal Cell Carcinoma (refractory to anti-PD-1/PD-L1)	2	Pembrolizumab + Aldesleukin	Recruiting	29
NCT05296564	NY-ESO-1 Expressing Metastatic Cancers	1 / 2	Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes + Cyclophosphamide + Aldesleukin	Recruiting	32
NCT03850691	Melanoma	2	Radiation + Nivolumab + Ipilimumab + Aldesleukin	Completed	33
NCT05802056	Gastric Cancer with Peritoneal Metastasis	1b	Aldesleukin + Nivolumab + FOLFOX Chemotherapy	Recruiting	34
NCT01160445	Metastatic Melanoma, Metastatic Renal Cancer	2	Zanolimumab (anti-CD4 mAb) + Aldesleukin	Active, not recruiting	35
N/A	Metastatic Uveal Melanoma	Active	Cyclophosphamide + Fludarabine + TILs + Aldesleukin	Active	31
N/A	Metastatic Biliary Tract Cancers	Active	Cell Therapy (TILs) + Aldesleukin	Active	31

Section 4: Safety, Tolerability, and Risk Management

The clinical utility of Aldesleukin is fundamentally constrained by its formidable toxicity profile. The potent, non-specific immune stimulation that drives its efficacy is also the source of severe, systemic, and potentially fatal adverse reactions. This risk profile dictates the need for administration in a specialized inpatient setting with intensive care capabilities and makes meticulous patient selection and risk management paramount.

Black Box Warning: Capillary Leak Syndrome (CLS)

Aldesleukin carries a prominent black box warning from the FDA for Capillary Leak Syndrome, its most characteristic and dangerous toxicity.[8]

• Pathophysiology: CLS is a systemic disorder that begins almost immediately after treatment initiation. It is caused by Aldesleukin-induced damage to the vascular endothelium, leading to a profound loss of vascular tone and a dramatic increase in capillary permeability. This allows massive amounts of plasma proteins and fluid to leak from the intravascular compartment into the extravascular space.[4]
• Clinical Manifestations: The hallmark of CLS is the rapid onset of severe hypotension (low blood pressure) and widespread edema (swelling) due to fluid shifting. Patients experience a significant gain in weight from this fluid retention. The loss of intravascular volume leads to reduced organ perfusion, meaning vital organs do not receive adequate blood flow.[5]
• Life-Threatening Sequelae: The systemic hypoperfusion caused by CLS can trigger a cascade of severe complications affecting multiple organ systems. These include [4]:
• Cardiovascular: Severe cardiac arrhythmias (both supraventricular and ventricular), angina, and myocardial infarction (heart attack).
• Pulmonary: Respiratory insufficiency, pulmonary edema, and acute respiratory distress syndrome (ARDS) that may require mechanical ventilation.
• Renal: Acute renal insufficiency and failure.
• Gastrointestinal: GI bleeding or infarction (tissue death due to lack of blood supply).
• Neurologic: Altered mental status.
• Management: Management of CLS requires vigilant monitoring in an intensive care unit (ICU). This includes tracking blood pressure, heart rate, fluid balance (via central venous pressure monitoring), and organ function. Treatment is supportive and aimed at maintaining organ perfusion. This may involve the administration of vasopressor drugs like dopamine or phenylephrine to raise blood pressure. Subsequent doses of Aldesleukin must be withheld until organ perfusion is restored and the patient is stabilized.[6]

Systemic Adverse Events by Organ System

Beyond CLS, Aldesleukin causes a wide spectrum of adverse events affecting nearly every organ system.

• Constitutional: A severe flu-like syndrome is nearly universal, characterized by high fever, rigors, and chills. This reaction typically requires premedication and ongoing management with antipyretics like acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), or, for severe rigors, meperidine.[5] Malaise, fatigue, and asthenia are also extremely common.[8]
• Cardiovascular: In addition to CLS-related events, tachycardia is very common. Myocarditis and arrhythmias have been reported.[4]
• Renal: Renal dysfunction with oliguria (decreased urine output) or anuria (no urine output) is a frequent and serious toxicity, often occurring as a direct consequence of CLS-induced renal hypoperfusion. It is correlated with the dose and duration of treatment. The risk is potentiated by the concomitant use of other nephrotoxic drugs or NSAIDs, which can impair renal blood flow.[6]
• Neurologic: CNS toxicity is dose-related and common. It can manifest as moderate-to-severe lethargy, somnolence, confusion, agitation, disorientation, and hallucinations. These symptoms can progress to obtundation and coma, which necessitates immediate discontinuation of the drug. While often reversible, some neurologic effects, such as demyelinating polyneuropathy, may be irreversible.[5]
• Gastrointestinal: Nausea, vomiting, and diarrhea are reported in the majority of patients. Stomatitis (inflammation of the mouth) and anorexia (loss of appetite) are also very common.[4]
• Hematologic: The drug's effect on the bone marrow and blood cells is characteristic. Profound anemia and thrombocytopenia (low platelet count) are common and can be dose-limiting. In contrast, marked eosinophilia (an increase in eosinophils) is a typical finding.[5] Impaired neutrophil function (reduced chemotaxis) has also been observed, increasing the risk of bacterial infections.[10]
• Hepatic: Liver toxicity is common, typically manifesting as elevated liver enzymes (AST) and hyperbilirubinemia (jaundice).[4]
• Dermatologic: Rash and pruritus (itching) are frequently observed.[8]
• Autoimmune Phenomena: The powerful immune stimulation can trigger or exacerbate autoimmune conditions. This includes worsening of pre-existing diseases like Crohn's disease, myasthenia gravis, or vasculitis. It can also induce new autoimmune disorders, most commonly thyroiditis, which may present first as hyperthyroidism followed by hypothyroidism. Development of diabetes mellitus has also been reported.[6]

Contraindications

Given the extreme toxicity, stringent patient selection is essential to minimize the risk of fatal adverse events. Aldesleukin is contraindicated in patients with [4]:

• Significant Organ Impairment: Patients with pre-existing and clinically significant cardiac, pulmonary (e.g., FEV1 < 2 liters), renal, hepatic, or CNS disease should not receive the drug.
• Organ Allografts: It is absolutely contraindicated in patients who have received an organ transplant, as the intense immune stimulation creates a very high risk of acute graft rejection.
• Active Infections: Pre-existing bacterial infections must be adequately treated prior to initiating Aldesleukin therapy due to the risk of impaired neutrophil function and disseminated infection.

Significant Drug Interactions

The potential for interactions with other medications is high, primarily due to Aldesleukin's effects on organ function and the immune system.

• Corticosteroids: Concomitant use with glucocorticoids (e.g., dexamethasone, prednisone) should be avoided, as their immunosuppressive effects may antagonize the desired antitumor activity of Aldesleukin.[4] However, in cases of life-threatening toxicity, intravenous dexamethasone may be administered as an emergency intervention.[10]
• Nephrotoxic, Hepatotoxic, or Myelotoxic Agents: Drugs that are toxic to the kidneys, liver, or bone marrow can have additive toxicity when given with Aldesleukin.
• Antihypertensive Medications: Can exacerbate the severe hypotension caused by Aldesleukin.
• Cytotoxic Chemotherapy: Concomitant administration with certain chemotherapeutic agents, such as cisplatin, dacarbazine, and vinblastine, may increase the risk of toxicity.[4]
• Iodinated Contrast Media: A peculiar and important interaction has been observed where patients who have recently received Aldesleukin can experience delayed hypersensitivity reactions to iodinated contrast agents used for imaging scans (e.g., CT scans). These reactions can occur weeks to months after Aldesleukin therapy.[6]

The unrelenting severity of this safety profile is the single most important factor that has shaped Aldesleukin's clinical and commercial history. It is not merely a list of potential side effects; it is the central challenge of the therapy. This challenge necessitated the development of specialized treatment centers, drove the search for predictive biomarkers to select only the most robust patients, and ultimately led to its displacement by safer alternatives. Most importantly, this toxicity profile created the powerful and enduring scientific rationale for the entire field of next-generation IL-2 engineering, which is fundamentally dedicated to decoupling the efficacy of IL-2 from its hazardous effects.

Section 5: Commercial and Regulatory Trajectory

The commercial history of Aldesleukin (Proleukin®) is a compelling case study in the lifecycle of a high-risk, high-reward niche oncology drug. Its journey traces a path from a pioneering product launched by a major biotech, through a period of divestment as newer therapies emerged, to its current status as a strategic asset for a company focused on next-generation cell therapy.

Regulatory Milestones

Proleukin's entry into the market was marked by two key approvals from the U.S. Food and Drug Administration (FDA), establishing it as a treatment for two difficult-to-treat metastatic cancers.

• Initial FDA Approval for Metastatic Renal Cell Carcinoma (mRCC): Proleukin was first approved on May 5, 1992, for the treatment of adults with mRCC.[1] This landmark approval was granted by the FDA based on clinical data demonstrating that high-dose Aldesleukin could induce durable complete responses, a feat that was remarkable at the time, even with a relatively low overall response rate.[1]
• FDA Approval for Metastatic Melanoma: Following its success in mRCC, the drug was granted Orphan Drug Designation for metastatic melanoma on September 10, 1996.[24] This was followed by full marketing approval for the treatment of adults with metastatic melanoma on January 9, 1998.[22] This approval was again based on its ability to produce durable responses in a small fraction of patients.[22]

Commercial History and Corporate Lineage

The ownership of Proleukin has changed hands multiple times, with each transition reflecting the evolving strategic value of the drug within the broader oncology market.

1. Chiron Corporation: Proleukin was originally developed and brought to market by Chiron Corporation, one of the pioneering biotechnology companies of its era. Chiron was the original sponsor for the BLA (Biologics License Application) and managed its initial launch and commercialization.[24]
2. Novartis: Through its acquisition of Chiron, the global pharmaceutical giant Novartis inherited the rights to Proleukin and continued to market the drug for several years.[26] During this period, newer, safer, and more broadly effective cancer immunotherapies, particularly checkpoint inhibitors, began to enter the market. As Proleukin's sales became a smaller part of Novartis's vast oncology portfolio (generating approximately $60 million in the U.S. in the year to June 2018), it became a non-core asset ripe for divestment.[41]
3. Prometheus Laboratories: At one point in its history, the U.S. rights to Proleukin were acquired by Prometheus Laboratories, a specialty pharmaceutical and diagnostics company, which continued its commercialization in the United States.[18]
4. Clinigen Group: The UK-based Clinigen Group, a company specializing in acquiring and managing niche hospital products, executed a strategic consolidation of Proleukin's global rights.

• In July 2018, Clinigen acquired the rights to Proleukin for all territories outside of the United States.[42]
• In February 2019, Clinigen completed the acquisition of the U.S. rights from Novartis for a total consideration of up to $210 million. This deal consisted of a $120 million upfront payment, $60 million in deferred payments, and up to $30 million in sales-related milestones. This transaction made Clinigen the sole global owner of Proleukin.[41]

5. Iovance Biotherapeutics: The most recent and strategically most significant transition occurred in 2023. Iovance Biotherapeutics, a late-stage biotechnology company focused on developing Tumor-Infiltrating Lymphocyte (TIL) therapies, acquired the worldwide rights to Proleukin from Clinigen.[44]

• The deal was announced in January 2023 and completed on May 18, 2023.[45]
• The financial terms were substantial, reflecting Proleukin's newfound strategic value. The deal included an upfront payment of £166.7 million (approximately $207.2 million), a future milestone payment of £41.7 million (approximately $52.6 million) contingent upon the first FDA approval of Iovance's lead TIL therapy (lifileucel), and ongoing double-digit royalties on global net sales payable to Clinigen.[44] The total cost of the acquisition was accounted for by Iovance as approximately $222.7 million, including transaction costs.[45]

Strategic Rationale for the Iovance Acquisition

The acquisition of Proleukin by Iovance was not a simple purchase of a revenue-generating asset; it was a critical vertical integration strategy driven by the fundamental biology of Iovance's core technology.[44]

• Securing a Mission-Critical Component: TIL therapy involves infusing a patient with their own expanded tumor-killing T-cells. For these cells to survive, proliferate, and effectively attack the cancer in vivo, they require potent stimulation from IL-2. Proleukin is the specific IL-2 product used in this regimen. By acquiring Proleukin, Iovance secured its supply chain for an absolutely essential component of its therapeutic platform.[48]
• Cost and Operational Control: Owning Proleukin allows Iovance to significantly lower its future cost of goods for its commercial TIL therapies and reduce the expenses associated with its ongoing clinical trials, as it no longer needs to purchase the drug on the open market. It also gives the company complete control over the manufacturing, logistics, and availability of Proleukin for patients who will be receiving their TIL treatments.[48]

The commercial journey of Proleukin perfectly illustrates the lifecycle of a pioneering but challenging pharmaceutical asset. It began as a flagship immunotherapy product, was later divested by big pharma as its market shrank, and was managed by a specialty pharma company that saw value in its established niche. The final chapter, its acquisition by Iovance, marks its ultimate transformation. Proleukin's value is no longer primarily as a standalone drug but as an indispensable enabling technology for a cutting-edge cell therapy platform. For Iovance, the strategic value of securing this critical reagent far exceeded the drug's standalone sales figures, justifying the significant acquisition cost.

Section 6: Aldesleukin in the Modern Immunotherapy Era: A Comparative Analysis

The therapeutic landscape of metastatic melanoma and renal cell carcinoma has been revolutionized since the approval of Aldesleukin. The advent of immune checkpoint inhibitors (CPIs) has established a new standard of care, offering improved efficacy and a significantly more manageable safety profile for a much broader patient population. A direct comparison of Aldesleukin to these modern agents is essential to understand its current place in the treatment algorithm.

The Paradigm Shift to Checkpoint Inhibitors

The approval of the first CPI, ipilimumab (an anti-CTLA-4 antibody), in 2011 marked the beginning of a new era.[50] This was rapidly followed by the development of anti-PD-1 antibodies, nivolumab and pembrolizumab, which proved to be both more effective and better tolerated than ipilimumab.[50] The use of these agents, either as monotherapy or in combination (e.g., ipilimumab plus nivolumab), has fundamentally altered treatment expectations and outcomes, relegating high-dose Aldesleukin to a niche role for highly selected patients.[52]

Comparative Efficacy in Metastatic Melanoma

When compared head-to-head based on data from pivotal clinical trials, the advantages of modern CPIs over Aldesleukin in the first-line treatment of metastatic melanoma become clear. This is summarized in Table 3.

• Aldesleukin: Historically, high-dose IL-2 therapy yields an objective response rate (ORR) of approximately 16%. Its most compelling feature is the 6% of patients who achieve a complete response (CR), many of which are exceptionally durable, lasting for many years and representing potential cures.[3]
• Ipilimumab (Monotherapy): The first CPI to show a survival benefit, ipilimumab produced a lower ORR of around 11%. However, it established the concept of a long-term survival "tail" on the Kaplan-Meier curve, with a pooled analysis showing a 3-year overall survival (OS) rate of 22%.[52]
• Anti-PD-1 Monotherapy (Nivolumab/Pembrolizumab): These agents represented a major step forward, demonstrating clear superiority over ipilimumab. They achieve ORRs in the range of 30-40% and have become a standard of care for first-line treatment.[51]
• Ipilimumab + Nivolumab Combination: This combination regimen currently offers the highest response rates, with a pivotal trial (CheckMate 067) reporting an ORR of 58%. The long-term follow-up from this trial is remarkable, showing a 6.5-year OS rate of 49%.[51] This superior efficacy, however, comes with substantial toxicity.
• Sequencing and Modern Context: For patients with BRAF-mutant melanoma, the DREAMSeq trial definitively showed that initiating treatment with the ipilimumab/nivolumab combination followed by BRAF/MEK targeted therapy upon progression resulted in a significantly better 2-year OS (72%) compared to the reverse sequence (52%).[51] This has cemented immunotherapy as the preferred first-line approach for most patients.

Comparative Efficacy in Metastatic Renal Cell Carcinoma

A similar paradigm shift has occurred in mRCC. While high-dose Aldesleukin can produce durable remissions in a select group of patients, with modern ORRs reaching 25% in prospective trials [1], the standard of care has moved towards combinations of CPIs with other CPIs or with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). These modern combination therapies have demonstrated superior efficacy compared to older TKI monotherapies like sunitinib and are now the established first-line treatments for most patients with mRCC.[53]

Safety and Tolerability Comparison

The most dramatic difference between Aldesleukin and modern CPIs lies in their safety profiles.

• Aldesleukin: As detailed previously, treatment is associated with severe, multi-system toxicities, dominated by Capillary Leak Syndrome. It requires mandatory hospitalization in an ICU setting and is associated with a treatment-related mortality rate.[4]
• Checkpoint Inhibitors: CPIs have their own distinct spectrum of immune-related adverse events (irAEs), which can affect any organ system (e.g., colitis, dermatitis, pneumonitis, endocrinopathies). While these can be serious or even fatal, they are generally more manageable than the toxicities of Aldesleukin. The rate of severe (Grade 3/4) adverse events for anti-PD-1 monotherapy is relatively low, around 10-14%.[51] The ipilimumab/nivolumab combination has a much higher rate of severe toxicity (~59%), approaching the level of concern seen with Aldesleukin, but it is still typically managed without the universal requirement for ICU care.[50]

Aldesleukin's Modern Niche

Given the clear advantages of CPIs in both efficacy and safety for the majority of patients, Aldesleukin is no longer considered a first-line therapy for either mRCC or metastatic melanoma. Its use is now reserved for specific, niche situations:

1. Salvage Therapy: For young, physically fit patients with excellent organ function who have progressed after treatment with standard CPIs and other available therapies. Early data from the PROCLAIM registry suggests that high-dose IL-2 can be administered safely after CPI failure and can still produce responses, with a reported ORR of approximately 18% in patients who received it after ipilimumab or anti-PD-1 therapy.[58]
2. Component of Adoptive Cell Therapy: As previously discussed, it remains an essential, non-discretionary agent for promoting the growth and function of infused TILs.[31]

Table 3: Comparative Efficacy of Immunotherapies in First-Line Metastatic Melanoma

Regimen	Objective Response Rate (ORR)	Complete Response (CR) Rate	Long-Term Overall Survival (OS)	Source(s)
Aldesleukin (High-Dose)	~16%	~6%	Durable responses in a small subset	3
Ipilimumab (anti-CTLA-4)	~11%	~2-3%	3-year OS: 22%	52
Nivolumab/Pembrolizumab (anti-PD-1)	~30-40%	~5-10%	6.5-year OS (Nivolumab): 42%	51
Ipilimumab + Nivolumab	~58%	~22%	6.5-year OS: 49%	51

This data-driven comparison provides an irrefutable rationale for the evolution of clinical practice. While Aldesleukin paved the way, the superior therapeutic index of checkpoint inhibitors has rightfully established them as the cornerstone of modern immunotherapy for melanoma and RCC.

Section 7: The Next Generation: Engineering a Safer and More Effective IL-2

The profound clinical impact and equally profound toxicity of Aldesleukin created a clear scientific mandate: to re-engineer the IL-2 molecule to retain its potent antitumor effects while shedding its dangerous side effects. This has led to a renaissance in IL-2-based drug development, with a variety of sophisticated strategies being employed to create safer, more selective, and more effective therapies.

The Rationale for Innovation: The IL-2 Dilemma

The central challenge of IL-2 therapy, and the primary driver of next-generation research, is the "IL-2 Dilemma." Aldesleukin's broad, non-specific activity is both its greatest strength and its greatest weakness.

• The Two Faces of the IL-2 Receptor: The key to this dilemma lies in the differential expression of the IL-2 receptor subunits on different immune cell populations.[20]
• Desired Target: The tumor-killing effector cells—CD8+ T-cells and Natural Killer (NK) cells—primarily express the intermediate-affinity IL-2 receptor, which consists of the IL-2Rβ (CD122) and IL-2Rγ subunits. Activation of these cells is the goal of therapy.
• Undesired Target: Immunosuppressive regulatory T-cells (Tregs) are characterized by high-level expression of the IL-2Rα subunit (CD25). This allows them to assemble the high-affinity trimeric IL-2R (αβγ). Activation of Tregs can dampen the antitumor immune response, working directly against the therapeutic goal. Furthermore, binding of IL-2 to receptors on vascular endothelial cells is thought to contribute to the severe toxicity of Capillary Leak Syndrome.
• The Goal of Engineering: Aldesleukin binds potently to both the intermediate- and high-affinity receptors, simultaneously activating cancer-fighting cells and immunosuppressive cells. The fundamental goal of next-generation IL-2 engineering is to create molecules that are biased, showing preferential binding and activation of the intermediate-affinity IL-2Rβγ on effector cells while minimizing or eliminating activation of the high-affinity IL-2Rαβγ on Tregs.[20]

Key Engineering Strategies

To solve the IL-2 dilemma, researchers have developed several elegant molecular engineering approaches [20]:

• Pegylation: This strategy involves covalently attaching large polyethylene glycol (PEG) chains to the IL-2 protein. By strategically placing the PEG chains near the IL-2Rα binding site, they can act as a physical shield, sterically hindering the molecule from interacting with CD25 on Tregs, thus biasing its activity toward the IL-2Rβγ complex on effector cells.[20]
• Amino Acid Mutagenesis ("Superkines"): Specific amino acids in the IL-2 protein can be changed through genetic engineering. Mutations can be introduced to disrupt the binding interface with IL-2Rα, while other mutations can be introduced to enhance the binding affinity for IL-2Rβ. This creates "superkines" with highly selective and potent activity on the desired cell types.[14]
• Fusion Proteins: IL-2 can be fused to other protein domains to alter its properties. A key example is fusing IL-2 to a portion of its own receptor (IL-2Rα), which effectively "pre-blocks" its ability to bind to CD25 on Tregs, forcing it to interact only with the βγ receptor complex.[20] Fusion to proteins like human albumin can also dramatically extend the molecule's half-life.[59]
• Immunocytokines: This approach fuses a modified IL-2 molecule to an antibody that specifically targets a protein found on the surface of tumor cells (a tumor-associated antigen). This is designed to concentrate the cytokine's activity directly within the tumor microenvironment, increasing local efficacy while reducing systemic toxicity.[20]

Case Study 1: Bempegaldesleukin (NKTR-214) - A Cautionary Tale

Bempegaldesleukin was a highly anticipated next-generation IL-2 that ultimately failed to meet its clinical endpoints, providing a crucial lesson for the field.

• Design: Bempegaldesleukin is a prodrug of Aldesleukin, modified with six releasable PEG chains. The PEGylation was designed to block binding to IL-2Rα on Tregs and, upon slow release of the PEG chains in the body, provide sustained signaling through the IL-2Rβγ pathway on CD8+ T-cells and NK cells.[60]
• Clinical Trial Results: Despite promising Phase 2 data, the large, pivotal Phase 3 trials in combination with the anti-PD-1 antibody nivolumab were major disappointments.
• PIVOT IO 001 (Metastatic Melanoma): The combination of bempegaldesleukin plus nivolumab failed to improve outcomes compared to nivolumab alone. The ORR was actually lower in the combination arm (27.7% vs. 36.0%), and both progression-free survival (PFS) and overall survival (OS) were not improved. Furthermore, the combination led to a higher rate of adverse events.[66]
• PIVOT-09 (mRCC): Similarly, the combination did not demonstrate improved efficacy over standard-of-care TKIs (sunitinib or cabozantinib), with an ORR of 23.0% for the combination versus 30.6% for the TKI arm.[68]
• Implication: The failure of bempegaldesleukin underscores the immense complexity of translating an elegant biological hypothesis into clinical success. It serves as a powerful reminder that factors such as in vivo pharmacokinetics, prodrug activation rates, and the intricate biology of the tumor microenvironment can thwart even well-designed molecules.

Case Study 2: Nemvaleukin Alfa (ALKS 4230) - A Promising Alternative

Nemvaleukin alfa utilizes a different engineering strategy and has shown more encouraging results in early clinical development.

• Design: Nemvaleukin is a novel fusion protein. It consists of a circularly permuted IL-2 molecule that is stably fused to the extracellular domain of the IL-2Rα chain. This unique design sterically occludes the molecule from binding to the high-affinity IL-2R on Tregs, thereby selectively directing its activity to the intermediate-affinity IL-2R on NK cells and CD8+ T-cells.[63]
• Clinical Trial Results (ARTISTRY-1): This Phase 1/2 study yielded promising data in heavily pretreated patients with advanced solid tumors.
• Monotherapy: Achieved an ORR of 10% in patients with refractory melanoma and mRCC.
• Combination with Pembrolizumab: Showed an ORR of 13% across a range of tumor types, including five complete responses. Notably, responses were seen in patients with platinum-resistant ovarian cancer, a disease that is typically unresponsive to immunotherapy.
• Safety and Administration: The drug was well tolerated, with a manageable safety profile. The most common severe adverse event was transient neutropenia, and very few patients discontinued due to toxicity. Crucially, it could be administered safely in an outpatient setting, a major advantage over high-dose Aldesleukin.[64]
• Implication: The positive results from nemvaleukin, contrasted with the failure of bempegaldesleukin, highlight that the specific engineering approach matters immensely. The fusion protein design of nemvaleukin appears to be a more effective strategy for achieving the desired selective activation of effector immune cells in a clinical setting.

Case Study 3: MDNA11 - An IL-2 "Superkine"

MDNA11 represents another distinct approach, focusing on enhancing affinity for the desired receptor.

• Design: MDNA11 is an IL-2 "Superkine" that has been engineered with several amino acid mutations. These mutations achieve two goals: they increase the molecule's binding affinity for the IL-2Rβ subunit by approximately 200-fold compared to native IL-2, and they completely eliminate its ability to bind to the IL-2Rα subunit. To overcome the short half-life of IL-2, it is also fused to human recombinant albumin, extending its duration of action and allowing for less frequent dosing (e.g., once weekly).[59]
• Preclinical and Non-Human Primate (NHP) Results: In preclinical tumor models, MDNA11 demonstrated strong single-agent antitumor activity and synergy with checkpoint inhibitors. In NHP safety studies, the molecule was well-tolerated and induced a potent and durable expansion of lymphocytes without significantly increasing Tregs or eosinophils (the latter being a cell type linked to the risk of vascular leak syndrome).[62] These promising non-clinical results support its ongoing clinical development.

The dynamic landscape of IL-2 engineering, summarized in Table 4, illustrates a field that has learned directly from the challenges of Aldesleukin. By developing a variety of sophisticated strategies, researchers are moving ever closer to unlocking the full therapeutic potential of this powerful cytokine pathway while minimizing its historical toxicities.

Table 4: Comparison of Aldesleukin and Next-Generation IL-2 Analogs

Feature	Aldesleukin (Proleukin®)	Bempegaldesleukin (NKTR-214)	Nemvaleukin Alfa (ALKS 4230)	MDNA11
Engineering Strategy	Recombinant protein with minor modifications for stability	PEGylated prodrug (6 releasable PEG chains)	Stable fusion protein (circularly permuted IL-2 fused to IL-2Rα domain)	IL-2 "Superkine" (mutations for receptor selectivity) fused to human albumin
Target Receptor Preference	Non-selective; binds both high-affinity (Treg) and intermediate-affinity (Effector cell) receptors	Designed to be IL-2Rβγ (Effector) preferential by sterically blocking IL-2Rα	Strictly IL-2Rβγ (Effector) preferential; sterically occluded from binding IL-2Rα	Strictly IL-2Rβγ (Effector) preferential; enhanced affinity for IL-2Rβ, no affinity for IL-2Rα
Key Advantage Goal	Potent, broad immune stimulation	Sustained signaling to effector cells, reduced Treg activation, outpatient use	Selective expansion of CD8+ T/NK cells, minimal Treg activation, outpatient use, manageable safety	Highly potent/selective effector cell activation, extended half-life, reduced dosing frequency
Clinical/Preclinical Outcome Summary	Effective but highly toxic; requires ICU care. Cures a small subset of patients.	Failure. Phase 3 trials did not meet primary endpoints for melanoma or RCC; added toxicity.	Promising. Showed monotherapy and combination activity in refractory tumors with a manageable safety profile.	Promising. Strong preclinical and NHP data showing potent, selective immune activation and good tolerability.
Source(s)	1	65	63	59

Conclusion and Expert Recommendations

Aldesleukin (Proleukin®) stands as a monumental, if deeply flawed, achievement in medical oncology. Its legacy is one of paradox: it was the drug that first validated the core principle of cancer immunotherapy, proving that stimulating the body's own defenses could produce complete and durable cures in patients with advanced metastatic disease. Yet, this remarkable power was harnessed through a mechanism of such brute force that its associated toxicities, particularly Capillary Leak Syndrome, are among the most severe in the pharmacopeia. This duality has defined its entire clinical and commercial existence.

The analysis presented in this report leads to a clear conclusion about its contemporary standing. With the advent of safer and more broadly effective immune checkpoint inhibitors, Aldesleukin is no longer a first-line therapeutic option for metastatic melanoma or renal cell carcinoma. Its current clinical value is confined to two specific niches. First, as a potential salvage therapy for a very select group of young, robust patients who have exhausted standard options. Second, and more significantly, as an indispensable component of modern adoptive cell therapies. The strategic acquisition of Proleukin by Iovance Biotherapeutics, a leader in TIL therapy, is the ultimate testament to this new role. Aldesleukin has transformed from a standalone drug into a critical enabling reagent for one of the most promising new modalities in cancer treatment.

The path forward for IL-2-based therapy lies not with Aldesleukin itself, but with the diverse and sophisticated next-generation analogs it inspired. The clinical journey of these new molecules, marked by both high-profile failures like bempegaldesleukin and promising early successes like nemvaleukin alfa, provides invaluable lessons for the field. The goal is no longer simply to stimulate the immune system, but to do so with precision, selectivity, and a manageable safety profile.

Based on this comprehensive review, the following expert recommendations are proposed:

1. Prioritize Continued Clinical Development of Selective IL-2 Analogs: The promising early data for molecules like nemvaleukin alfa and the strong preclinical rationale for agents like MDNA11 warrant continued and rigorous clinical investigation. The focus should remain on agents that have demonstrated a clear ability to preferentially activate effector immune cells (CD8+ T-cells, NK cells) over immunosuppressive regulatory T-cells. Development should prioritize both monotherapy and rational combination strategies with other immunotherapies, such as checkpoint inhibitors and cell therapies.
2. Intensify Predictive Biomarker Research: A critical lesson from the Aldesleukin era is that patient selection is key to optimizing the risk-benefit ratio. This principle is even more crucial for the next generation of therapies. Research efforts must be dedicated to identifying predictive biomarkers—whether based on tumor genetics, protein expression (e.g., PD-L1), or peripheral immune cell profiling—that can identify the patients most likely to respond to a specific IL-2 analog. This will maximize efficacy, avoid exposing non-responders to potential toxicity, and guide the development of personalized immunotherapy regimens.
3. Explore Novel Engineering and Delivery Strategies: The field should continue to build upon the engineering strategies that have shown the most promise, such as the fusion protein approach of nemvaleukin. Concurrently, exploration of novel delivery systems, including tumor-targeted immunocytokines and mRNA-based therapies that allow for localized in vivo production of cytokines, should be pursued. These strategies hold the potential to further refine the therapeutic window, concentrating the potent effects of IL-2 within the tumor microenvironment while minimizing systemic exposure and toxicity.

In conclusion, Aldesleukin's chapter as a frontline cancer therapy may have closed, but its influence endures. It serves as both a critical tool for today's most advanced cell therapies and as the scientific foundation upon which a safer, more effective future for the entire IL-2 pathway is being built.

Works cited

1. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma - PMC - PubMed Central, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4315731/
2. Interleukin-2 (IL-2, Aldesleukin, PROLEUKIN®) - Melanoma Research Alliance, accessed July 23, 2025, https://www.curemelanoma.org/patient-eng/melanoma-treatment/options/interleukin-2-il-2-aldesleukin-proleukin
3. An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8510610/
4. HUMAN IL-2 | 110942-02-4 - ChemicalBook, accessed July 23, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3161838.htm
5. DRUG NAME: Aldesleukin - BC Cancer, accessed July 23, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Aldesleukin_monograph.pdf
6. aldesleukin - Cancer Care Ontario, accessed July 23, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43881
7. Proleukin (Aldesleukin for Injection): Side Effects, Uses, Dosage, Interactions, Warnings, accessed July 23, 2025, https://www.rxlist.com/proleukin-drug.htm
8. Aldesleukin Monograph for Professionals - Drugs.com, accessed July 23, 2025, https://www.drugs.com/monograph/aldesleukin.html
9. Definition of aldesleukin - NCI Drug Dictionary, accessed July 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aldesleukin
10. How to order PROLEUKIN® (aldesleukin) Recombinant IL-2, accessed July 23, 2025, https://www.proleukin.com/
11. CAS 110942-02-4 | Sigma-Aldrich, accessed July 23, 2025, https://www.sigmaaldrich.com/US/en/search/110942-02-4?focus=products&page=1&perpage=30&sort=relevance&term=110942-02-4&type=cas_number
12. Aldesleukin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 23, 2025, https://go.drugbank.com/drugs/DB00041
13. CAS 110942-02-4 Aldesleukin - BOC Sciences, accessed July 23, 2025, https://www.bocsci.com/product/aldesleukin-cas-110942-02-4-160629.html
14. IL-2 (human): FC (human) HEK 293 cells, 95 SDS-PAGE 110942-02-4 - Sigma-Aldrich, accessed July 23, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/srp8034
15. Aldesleukin; Recombinant Modified Human interleukin-2 - Therapeutic Proteins, accessed July 23, 2025, https://therapeutic.creativebiomart.net/aldesleukin-recombinant-modified-human-interleukin-2.html
16. Proleukin (aldesleukin) injection label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
17. Label: PROLEUKIN- aldesleukin injection, powder, lyophilized, for solution - DailyMed, accessed July 23, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=deead498-9f19-48cf-87c7-6caf2263f2ab
18. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S., accessed July 23, 2025, https://www.prnewswire.com/news-releases/prometheus-acquires-exclusive-rights-to-proleukinr-aldesleukin-in-the-us-82670677.html
19. www.cancer.gov, accessed July 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aldesleukin#:~:text=Aldesleukin%20binds%20to%20and%20activates,in%20an%20activated%20receptor%20complex.
20. The next generation of cancer immunotherapies: re-exploring the IL-2 pathway, accessed July 23, 2025, https://www.sciencworldpublishing.org/news/the-next-generation-of-cancer-immunotherapies-re-exploring-the-il-2-pathway
21. aldesleukin - Cancer Care Ontario, accessed July 23, 2025, https://www.cancercareontario.ca/en/system/files_force/aldesleukin.pdf?download=1
22. CIS - Aldesleukin - Clinical Immunology Society, accessed July 23, 2025, https://clinimmsoc.org/Table-of-Compounds/Aldesleukin.htm
23. www.pharmakb.com, accessed July 23, 2025, https://www.pharmakb.com/drug-report/aldesleukin#:~:text=Proleukin%20(aldesleukin)%20is%20a%20protein,on%201992%2D05%2D05.
24. Search Orphan Drug Designations and Approvals - FDA, accessed July 23, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=100696
25. Aldesleukin Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV) Infections Treatment | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00041/clinical_trials?conditions=DBCOND0035016&phase=1&purpose=treatment&status=completed
26. Aldesleukin - Clinigen/Novartis - AdisInsight - Springer, accessed July 23, 2025, https://adisinsight.springer.com/drugs/800008892
27. Aldesleukin Completed Phase 2 / 3 Trials for Lymphoma Treatment | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00041/clinical_trials?conditions=DBCOND0006647&phase=2%2C3&purpose=treatment&status=completed
28. Aldesleukin Completed Phase 2 Trials for Brain and Central Nervous System Tumors Treatment - DrugBank, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00041/clinical_trials?conditions=DBCOND0028448&phase=2&purpose=treatment&status=completed
29. Renal Cell Carcinoma Metastatic Recruiting Phase 2 Trials for Aldesleukin (DB00041), accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0118133/clinical_trials/DB00041?phase=2&status=recruiting
30. Study Details | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | ClinicalTrials.gov, accessed July 23, 2025, https://www.clinicaltrials.gov/study/NCT05155033
31. Clinical Trials Using Aldesleukin - NCI, accessed July 23, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/aldesleukin?pn=1
32. Metastatic Melanoma Stage IV Recruiting Phase 1 / 2 Trials for Aldesleukin (DB00041), accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0068670/clinical_trials/DB00041?phase=1%2C2&status=recruiting
33. Aldesleukin Completed Phase 2 Trials for Metastatic Melanoma Treatment - DrugBank, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00041/clinical_trials?conditions=DBCOND0030058&phase=2&purpose=treatment&status=completed
34. Aldesleukin in Combination with Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer with Peritoneal Metastasis, CONTROL Study - NCI, accessed July 23, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02250
35. Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | ClinicalTrials.gov, accessed July 23, 2025, https://www.clinicaltrials.gov/study/NCT01160445
36. Aldesleukin Uses, Side Effects & Warnings - Drugs.com, accessed July 23, 2025, https://www.drugs.com/mtm/aldesleukin.html
37. Proleukin Uses, Side Effects & Warnings - Drugs.com, accessed July 23, 2025, https://www.drugs.com/mtm/proleukin.html
38. Aldesleukin (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/aldesleukin-intravenous-route/description/drg-20061519
39. aldesleukin - Drug Central, accessed July 23, 2025, https://drugcentral.org/drugcard/5011
40. Aldesleukin - PubChem, accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Aldesleukin
41. Novartis to divest Proleukin's US rights to Clinigen for $210m - Pharmaceutical Technology, accessed July 23, 2025, https://www.pharmaceutical-technology.com/news/novartis-divests-proleukin-us-rights/
42. Clinigen completes acquisition of US rights to Proleukin, accessed July 23, 2025, https://www.clinigengroup.com/news/news-container/2019/clinigen-completes-acquisition-of-us-rights-to-proleukin/
43. Clinigen acquires global rights to Proleukin® outside the United States, accessed July 23, 2025, https://www.clinigengroup.com/media/1459/clinigen-peroni-press-release-17july2018.pdf
44. Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million - BioSpace, accessed July 23, 2025, https://www.biospace.com/clinigen-divests-proleukin-to-iovance-biotherapeutics-for-166-7-million
45. proleukin acquisition - SEC.gov, accessed July 23, 2025, https://www.sec.gov/Archives/edgar/data/1425205/000155837023013988/R11.htm
46. Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million, accessed July 23, 2025, https://www.clinigengroup.com/news/news-container/2023/clinigen-divests-proleukin-to-iovance-biotherapeutics-for-1667-million/
47. On January 23, 2023, the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the “Option Agreement”) with Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc. (collectively, “Clinigen”), a global pharmaceutical services company, pursuant to which the Purchaser would acquire the worldwide rights for the manufacturing, supply, commercialization and sale of Proleukin ® (aldesleukin) (the “Acquisition”). - SEC.gov, accessed July 23, 2025, https://www.sec.gov/Archives/edgar/data/1425205/000155837024014905/R11.htm
48. Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates, accessed July 23, 2025, https://ir.iovance.com/node/13881/pdf
49. DLA Piper advises Iovance Biotherapeutics, Inc. in its acquisition of Proleukin, accessed July 23, 2025, https://www.dlapiper.com/en-NL/news/2023/01/dla-piper-advises-iovance-biotherapeutics-in-its-acquisition-of-proleukin
50. Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations - Frontiers, accessed July 23, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1187840/epub
51. Curing Stage IV Melanoma: Where Have We Been and Where Are We?, accessed July 23, 2025, https://ascopubs.org/doi/10.1200/EDBK_438654
52. Update on use of aldesleukin for treatment of high-risk metastatic melanoma - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4918260/
53. What Makes Immunotherapy for Kidney Cancer a Promising Treatment?, accessed July 23, 2025, https://www.cancerresearch.org/immunotherapy-by-cancer-type/kidney-cancer
54. Melanoma Cancer - Cancer Research Institute, accessed July 23, 2025, https://www.cancerresearch.org/immunotherapy-by-cancer-type/melanoma-cancer
55. Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma, accessed July 23, 2025, https://www.mdpi.com/2072-6694/12/8/2329
56. Evolving Management of Stage IV Melanoma - ASCO Publications, accessed July 23, 2025, https://ascopubs.org/doi/10.1200/EDBK_397478
57. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy - ASCO Publications, accessed July 23, 2025, https://ascopubs.org/doi/10.1200/EDBK_280817
58. A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC). - ASCO Publications, accessed July 23, 2025, https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.3053
59. MDNA11 | Pipeline | Medicenna, accessed July 23, 2025, https://www.medicenna.com/pipeline/mdna11/
60. Bempegaldesleukin - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Bempegaldesleukin
61. Transforming cancer treatment with next-generation cytokines - News-Medical.net, accessed July 23, 2025, https://www.news-medical.net/whitepaper/20241216/Transforming-cancer-care-with-next-generation-cytokines.aspx
62. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate | Journal for ImmunoTherapy of Cancer, accessed July 23, 2025, https://jitc.bmj.com/content/10/1/e003155
63. nemvaleukin alfa - NCI Drug Dictionary, accessed July 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nemvaleukin-alfa
64. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy ..., accessed July 23, 2025, https://jitc.bmj.com/content/12/11/e010143
65. Definition of bempegaldesleukin - NCI Drug Dictionary, accessed July 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bempegaldesleukin
66. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results - ASCO Publications, accessed July 23, 2025, https://ascopubs.org/doi/10.1200/JCO.23.00172
67. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/37651676/
68. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/38838287/
69. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39567211/
70. Nemvaleukin Alfa Shows Promising Activity in Advanced Solid Tumors - CancerNetwork, accessed July 23, 2025, https://www.cancernetwork.com/view/nemvaleukin-alfa-shows-promising-activity-in-advanced-solid-tumors
71. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/35058325/